12 completed, 4 terminated, 3 withdrawn, 2 not yet recruiting. 26 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 26 | Completed 12, Terminated 4, Withdrawn 3, Not yet recruiting 2, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Unknown 1 |
Follow Sickle Cell Disease: new trials by email Literature Review of Sickle Cell Disease trials Research Report on Sickle Cell Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis Group 02 Paracetamol + Morphine + Ketamine, Group 01 Control: Paracetamol + Morphine, Group 03 : Paracetamol + Morphine + Nefopam - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2026-10-01 | 2026-09-18 |
| Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease Prophylactic Transfusion Intervention group: Transfusion, Control group - Sickle Cell Disease, Pregnancy Related | Phase 4 | Withdrawn | Emory University | 2026-09-01 | 2026-10-19 | |
| Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease Ketorolac - Sickle Cell Disease, Sickle Cell Crisis | Phase 4 | Not yet recruiting | Children's Blood and Cancer Center at Dell Children's Medical Center | 102 | 2024-09-30 | 2024-08-30 |
| Stroke Prevention in Nigeria 2 Trial Hydroxyurea - Sickle Cell Disease, Stroke | Phase 4 | Recruiting | Vanderbilt University Medical Center | 220 | 2024-08-05 | 2026-03-05 |
| Voxelotor Brain Oxygenation and Neurocognitive Study Voxelotor Oral Tablet - Sickle Cell Disease | Phase 4 | Withdrawn | Pfizer | 2023-08-09 | 2024-08-09 | |
| Effects of the Contraceptive Implant in Women With Sickle Cell Disease Nexplanon 68 MG Drug Implant - Sickle Cell Disease | Phase 4 | Active not recruiting | University of Pennsylvania | 22 | 2023-08-02 | 2026-06-12 |
| A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study Mitapivat - Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 4 | Enrolling by invitation | Agios Pharmaceuticals, Inc. | 55 | 2023-07-06 | 2026-10-28 |
| Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient Clonidine - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 4 | Unknown | Centre Hospitalier Universitaire Saint Pierre | 40 | 2023-04-25 | 2023-05-08 |
| Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients L-Glutamine, Oral Powder for Reconstitution, Standard of care - Sickle Cell Disease | Phase 4 | Completed | Ain Shams University | 60 | 2022-01-04 | 2024-01-09 |
| Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study Crizanlizumab - Sickle Cell Disease | Phase 4 | Recruiting | Novartis Pharmaceuticals | 130 | 2021-06-10 | 2026-06-08 |
| Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients L-glutamine - Sickle Cell Disease, Pharmacokinetics | Phase 4 | Completed | Emmaus Medical, Inc. | 13 | 2021-01-04 | 2022-08-02 |
| Actigraphy Improvement With Voxelotor (ActIVe) Study Voxelotor - Sickle Cell Disease, Sickle Cell Anemia | Phase 4 | Completed | Pfizer | 25 | 2020-12-21 | 2023-11-21 |
| Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine, Hydroxycarbamide 500 Mg Oral Capsule, L-Carnitine, 250 Mg Oral Capsule - Sickle Cell Disease | Phase 4 | Completed | Assiut University | 91 | 2017-01-10 | 2021-10-22 |
| Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Rejuvesol, Blood transfusion - Sickle Cell Disease | Phase 4 | Completed | Duke University | 4 | 2016-12-01 | 2019-01-25 |
| Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients Vitamin E - Sickle Cell Disease | Phase 4 | Completed | Ain Shams University | 50 | 2016-06-01 | 2023-05-03 |
| Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Siklos - Sickle Cell Disease, Renal Function Disorder | Phase 4 | Completed | Theravia | 40 | 2015-09-03 | 2021-10-12 |
| Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Deferiprone - Iron Overload, Sickle Cell Disease | Phase 4 | Terminated | ApoPharma | 134 | 2015-05-21 | 2024-01-10 |
| Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Hydromorphone (Standardized, weight-based dosing), Morphine Sulfate (Standardized, weight-based dosing), Hydromorphone (Patient Specific dosing) - Sickle Cell Disease | Phase 4 | Completed | Duke University | 106 | 2015-03-15 | 2017-08-04 |
| Contraception in Women With Sickle Cell Disease etonogestrel-releasing implant contraceptive - Sickle Cell Disease | Phase 4 | Completed | University of Sao Paulo | 29 | 2015-01-01 | 2020-11-06 |
| Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment hydroxyurea - Sickle Cell Disease, Sickle Cell Anemia | Phase 4 | Completed | Loyola University | 53 | 2014-12-01 | 2023-03-09 |
Showing 20 of 26. Sign in to see all of them.
Anemia, Sickle Cell (26) · Vaso-Occlusive Crises (4) · Agnosia (3) · Iron Overload (2) · Pain (2) · Thalassemia (2) · Anemia (1) · Anemia, Hemolytic (1) · Emergencies (1) · Pyruvate Kinase Deficiency of Red Cells (1) · Stroke (1) · beta-Thalassemia (1)
Anemia, Hemolytic, Congenital (26) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26) · Genetic Diseases, Inborn (26) · Hematologic Diseases (26) · Hemic and Lymphatic Diseases (26) · Hemoglobinopathies (26) · Anemia (25) · Anemia, Hemolytic (25) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Neurobehavioral Manifestations (3) · Perceptual Disorders (3) · Iron Metabolism Disorders (2)
Morphine (5) · Hydroxyurea (4) · Deferiprone (2) · Deferoxamine (2) · Glutamine (2) · Ketamine (2) · etonogestrel (2) · voxelotor (2) · Antioxidants (1) · Blood Transfusion (1) · Carnitine (1) · Clonidine (1) · Codeine (1) · Control Groups (1) · Deferasirox (1)
Ain Shams University (2) · ApoPharma (2) · Duke University (2) · Pfizer (2) · Agios Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Boston Children's Hospital (1) · Centre Hospitalier Universitaire Saint Pierre (1) · Children's Blood and Cancer Center at Dell Children's Medical Center (1) · Children's Hospital of Philadelphia (1) · Children's National Research Institute (1) · Emmaus Medical, Inc. (1) · Emory University (1) · London North West Healthcare NHS Trust (1)
United States (13) · Brazil (4) · Egypt (4) · United Kingdom (4) · Belgium (3) · Canada (3) · France (3) · Turkey (Türkiye) (3) · Nigeria (2) · Saudi Arabia (2) · Colombia (1) · Germany (1) · Ireland (1) · Israel (1) · Italy (1)
Fatma SE Ebeid, MD (2) · Janet Kwiatkowski, MD (2) · Alicia Chang, MD (1) · Arjunan Ganesh, MD (1) · Bamidele O Tayo, PhD (1) · Caroline Dore, BSc (1) · Deborah Chirnomas, MD (1) · Gavin Cho, MD (1) · Ian J Welsby, BSc MBBS (1) · Israa EM Ashry, Prof (1) · Jay Raval, MD (1) · Julia C. Finkel, M.D. (1) · Kofi A Anie, PhD (1)
PMID 10100293, PMID 19724055, PMID 2082307, PMID 2666928, PMID 2689472, PMID 27288381, PMID 27993418, PMID 28238158, PMID 29756251, PMID 30663794, PMID 34847228, PMID 36018224, PMID 37807937, PMID 37975597, PMID 38401036, PMID 9620101
U01NS129143 (1)